Symbols

BVS

Bioventus·NASDAQ

--(--)

BVS fundamentals

BVS Q4 2025 Earnings

Bioventus (BVS) released its earnings on Mar 5, 2026: revenue was 157.90M (YoY +2.77%), beat estimates; EPS was 0.24 (YoY +60.00%), beat estimates.

Revenue / YoY

157.90M

+2.77%

EPS / YoY

0.24

+60.00%

Report date

Mar 5, 2026

BVS Earnings Call Summary for Q4,2025

Q4 Strong Finish: 10% organic revenue growth, $37M EBITDA, $38M cash flow. PNS/PRP pilots exceed expectations.
2025 Milestones: 150bp EBITDA margin expansion, $75M cash flow, Restorative Therapies record growth.
2026 Growth Plan: $13M investment in PNS/PRP/Ultrasonics, targeting 200+ basis points contribution. Maintain 20% EBITDA margin, reduce leverage below 2x.
Segment Outlook: Pain (+mid-single-digit), Surgical (+double-digit), Restorative (+low-mid-single-digit).

Earnings

EPS

Revenue

Revenue & Expenses

BVS has released its 2025 Q4 earnings report, with revenue of 157.90M, reflecting a YoY change of 2.77%, and net profit of 17.32M, showing a YoY change of 2971.97%. The Sankey diagram below clearly presents BVS's revenue sources and cost distribution.

Key Indicators

Bioventus (BVS) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Bioventus (BVS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Bioventus (BVS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Bioventus (BVS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown